JP3105307B2 - Continuous production of solubilized β-carotene - Google Patents
Continuous production of solubilized β-caroteneInfo
- Publication number
- JP3105307B2 JP3105307B2 JP03248638A JP24863891A JP3105307B2 JP 3105307 B2 JP3105307 B2 JP 3105307B2 JP 03248638 A JP03248638 A JP 03248638A JP 24863891 A JP24863891 A JP 24863891A JP 3105307 B2 JP3105307 B2 JP 3105307B2
- Authority
- JP
- Japan
- Prior art keywords
- carotene
- solubilized
- emulsifier
- heating coil
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 title claims description 30
- 235000013734 beta-carotene Nutrition 0.000 title claims description 30
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 title claims description 30
- 239000011648 beta-carotene Substances 0.000 title claims description 30
- 229960002747 betacarotene Drugs 0.000 title claims description 30
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 title claims description 30
- 238000010924 continuous production Methods 0.000 title claims description 6
- 239000003995 emulsifying agent Substances 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000000725 suspension Substances 0.000 claims description 7
- 239000012456 homogeneous solution Substances 0.000 claims description 5
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 3
- 150000001746 carotenes Chemical class 0.000 claims description 3
- 235000005473 carotenes Nutrition 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 claims description 3
- 239000000243 solution Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 238000006317 isomerization reaction Methods 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 4
- 125000006353 oxyethylene group Chemical group 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- -1 Ethoxylated sorbitan fatty acid esters Chemical class 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- MRWKWISFCDSNQN-UHFFFAOYSA-N 13-hydroxyoctadecanoic acid Chemical compound CCCCCC(O)CCCCCCCCCCCC(O)=O MRWKWISFCDSNQN-UHFFFAOYSA-N 0.000 description 2
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-Hydroxyoctadecanoic acid Natural products CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 238000010923 batch production Methods 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 150000004665 fatty acids Chemical group 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/24—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Colloid Chemistry (AREA)
Description
【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION
【0001】[0001]
【産業上の利用分野】本発明は、混合室法によるβ−カ
ロテン可溶化物(solubilizates)の連続的製造に関す
る。The present invention relates to the continuous production of β-carotene solubilizates by a mixed chamber process.
【0002】[0002]
【従来の技術】欧州特許(EP−B)第055817号
明細書中に記載されたバッチ法では、注射用のβ−カロ
テン水溶液は、乳化剤を用いて製造される。このため
に、乳化剤を170〜180℃に加熱し、かつβ−カロ
テンを融液中に導入する。この際、β−カロテンが部分
的異性化をともなって溶解する。約6分の滞留時間後
に、融液を95℃まで冷却し、かつ次いで水を初めは滴
下して導入し、かつ生成物を最終的に活性物質含有率
4.5%が得られるように水を用いて調節する。乳化剤
含有率は、通例約25%である。BACKGROUND OF THE INVENTION In the batch process described in EP-B 0 558 817, aqueous β-carotene solutions for injection are prepared using emulsifiers. For this, the emulsifier is heated to 170-180 ° C. and β-carotene is introduced into the melt. At this time, β-carotene dissolves with partial isomerization. After a residence time of about 6 minutes, the melt is cooled to 95.degree. C. and then water is initially introduced dropwise and the product is brought to an end with an active substance content of 4.5% by water. Adjust using. The emulsifier content is typically about 25%.
【0003】β−カロテンの低い溶解性故に、可溶化物
は、貯蔵試験での再結晶に関して、相当の安定性を示さ
なくてはならず、これは、好適な異性体比により得られ
る。従って、この明細書に相当する生成物の製造は、異
性化の調節を包含している。これは、記載のバッチ法
で、困難さを有してのみ達成される。[0003] Due to the low solubility of β-carotene, the solubilizates must exhibit considerable stability with respect to recrystallization in storage tests, which is obtained with a favorable isomer ratio. Thus, the preparation of the products corresponding to this specification involves modulation of the isomerization. This is achieved only with difficulty in the described batch process.
【0004】[0004]
【発明が解決しようとする課題】本発明の課題は、異性
化の調節を包含する連続的製造法を提案することを課題
とする。It is an object of the present invention to propose a continuous production process involving the control of the isomerization.
【0005】[0005]
【課題を解決するための手段】この課題は、β−カロテ
ンを乳化剤と一緒に短時間加熱して均質溶液を得、これ
を水の添加により100℃より低く急速冷却し、引き続
き所望の最終濃度のβ−カロテンに調節することによる
β−カロテン可溶化物の連続的製法により達成されるこ
とが判明し、これは、20〜80℃に前加熱された、乳
化剤中のβ−カロテン1〜40重量%の懸濁液を熱伝達
油中に置かれた加熱コイルにポンプ導通し(ここで可溶
化混合物は、120〜180℃であり、かつ滞留時間
は、10〜300秒である)、かつ均質溶液を圧力10
〜50バールで使用される混合室中で、かなりの量の水
と共に、10〜80℃で乱流混合させ、均質溶液を10
0℃より低く急速冷却して、β−カロテン0.5〜6重
量%から成る可溶化物を生ぜしめ、かつ必要に応じて所
望の最終濃度に希釈することよりなる。SUMMARY OF THE INVENTION This object is achieved by heating β-carotene with an emulsifier for a short time to obtain a homogeneous solution, which is rapidly cooled to below 100 ° C. by the addition of water, followed by the desired final concentration. It has been found that this can be achieved by a continuous process for the preparation of β-carotene solubilisate by adjusting to β-carotene in the emulsifier, preheated to 20-80 ° C. Pumping the wt% suspension through a heating coil placed in a heat transfer oil (where the solubilized mixture is 120-180 ° C. and the residence time is 10-300 seconds); and Homogeneous solution at pressure 10
Mix turbulently at 10-80 ° C. with a considerable amount of water in a mixing chamber used at 5050 bar,
Rapid cooling below 0 ° C. results in a solubilizer consisting of 0.5 to 6% by weight of β-carotene and, if necessary, dilution to the desired final concentration.
【0006】混合室は、水がβ−カロテン溶液に角度約
180°で当たるT形であってよい。混合室の形に関す
る決定的要点は、均質溶液及び水相の乱流混合を確実に
することである。[0006] The mixing chamber may be T-shaped, in which water impinges on the β-carotene solution at an angle of about 180 °. The crucial point for the shape of the mixing chamber is to ensure turbulent mixing of the homogeneous solution and the aqueous phase.
【0007】好適な乳化剤は、HLB(H.Pフィードラー
(Fiedler)、Lexikon der Pharmazie、Kosmetik und angr
enzenden Gebiete、1971、263〜270頁、特に
267〜269頁)12〜16を有する慣例の非−イオ
ン乳化剤、特に炭素原子12〜18個を有する脂肪酸の
エトキシル化オキシエチレン単位20〜60個を含有す
るトリグリセリド又はオキシエチレン単位約20個を有
するエトキシル化ソルビタン脂肪酸エステル又は西独特
許公開(DE−A)第2911241号明細書中に記載
されているオキシエチレン単位14〜17個を有するエ
トキシル化モノヒドロキシ脂肪酸である。この種の乳化
剤は、可溶化剤とも呼ばれる。それというのもこれら
は、水中に溶け、かつ従ってミセル溶液中にそれを保持
することにより、親油性物質の溶解性を促進するからで
ある。ミセル溶液は、透明性と澄明度に際立っている。
これらは、準弾性光散乱により測定されるようなミセル
の寸法を示すことにより特徴づけられる。使用される可
溶化剤及び活性物質の含有率に依り、直径は10〜10
0nmである。A preferred emulsifier is HLB (HP feeder)
(Fiedler), Lexikon der Pharmazie, Kosmetik und angr
enzenden Gebiete, 1971, pages 263-270, especially pages 267-269) containing customary non-ionic emulsifiers having 12-16, especially ethoxylated oxyethylene units of fatty acids having 12-18 carbon atoms. Ethoxylated sorbitan fatty acid esters having about 20 triglycerides or oxyethylene units or ethoxylated monohydroxy fatty acids having 14 to 17 oxyethylene units as described in DE-A-291 12 241 It is. This type of emulsifier is also called a solubilizer. Since they promote the solubility of lipophilic substances by dissolving in water and thus retaining it in micellar solution. Micellar solutions are distinguished by clarity and clarity.
These are characterized by exhibiting micelle dimensions as measured by quasi-elastic light scattering. Depending on the solubilizer and active substance content used, the diameter is 10 to 10
0 nm.
【0008】特に好適な非−イオン乳化剤の例は、次の
ものである:グリセロールポリオキシエチレングリコー
ルリシノレエート、グリセロールポリオキシエチレング
リコールヒドロキシステアレート、ポリオキシエチレン
(20)ソルビタンモノオレエート、ポリオキシポリオ
キシエチレン(20)ソルビタンモノオレエート、ポリ
オキシエチレン(20)ソルビタンモノステアレート及
びオキシエチレン15単位を有するモノヒドロキシステ
アリン酸。Examples of particularly suitable non-ionic emulsifiers are: glycerol polyoxyethylene glycol ricinoleate, glycerol polyoxyethylene glycol hydroxystearate, polyoxyethylene (20) sorbitan monooleate, poly Oxypolyoxyethylene (20) sorbitan monooleate, polyoxyethylene (20) sorbitan monostearate and monohydroxystearic acid having 15 units of oxyethylene.
【0009】可溶化物は、新規方法により、例えば次の
ような図1で図示したような装置を用いて製造される: 装置は、部分I、II及びIIIに分けられる。部分IIは、高
温部であり、部分I及びIIIの温度は、80℃より低い。The lysate is produced by a novel method, for example using an apparatus as shown in FIG. 1 as follows: The apparatus is divided into parts I, II and III. Part II is the hotter part, and the temperature of parts I and III is lower than 80 ° C.
【0010】酸化防止剤0.1〜10%が添加された又
は添加されていない、選択された乳化剤中のβ−カロテ
ンの濃度1〜40重量%、有利には10〜30重量%の
懸濁液を、容器(1)中に導入する。この懸濁液を20
〜80℃、有利には60〜70℃に調節する。ポンプ
(2)は連続的に、活性物質懸濁液を加熱コイル(3)
に供給する。加熱コイルは、加熱された熱伝達油中に置
かれている。ポンプ(2)の送り出し、加熱コイル
(3)の長さ及び熱伝達油の温度はそれぞれ、加熱コイ
ル中での懸濁液の滞留時間が、測定点(9)で測定した
120〜180℃の温度で10〜300sec(有利には
60sec)になるように調節する。この滞留時間の間
に、β−カロテンが同時の異性化を伴って可溶化剤中に
溶ける。加熱コイルから出る溶液を、同様にポンプ
(5)により容器(4)から混合室中に送られる水相と
混合室(6)中で乱流混合させる。ミセル状β−カロテ
ン溶液が混合室中で製造される。水相は、10〜80
℃、有利には25℃である。水相は、防腐剤、例えばベ
ンジルアルコールを最終生成物の0.5〜5%の濃度で
含有していてよい。混合室の可溶化物下流の温度を測定
位置(10)で測定すると、40〜80℃である。生成
物を、10〜50バールに調節した圧力調節機(7)を
介して容器(8)中に注ぐ。活性物質の含有率は、それ
ぞれの場合に選択される濃度及び流量に左右され、通常
は、0.5〜6%、有利には4%である。Suspension of the concentration of β-carotene in the selected emulsifier, with or without 0.1-10% of antioxidants, of 1-40% by weight, preferably 10-30% by weight. The liquid is introduced into the container (1). Add this suspension to 20
8080 ° C., preferably 60-70 ° C. The pump (2) continuously pumps the active substance suspension into the heating coil (3)
To supply. The heating coil is located in the heated heat transfer oil. The delivery of the pump (2), the length of the heating coil (3) and the temperature of the heat transfer oil were in each case between 120 and 180 ° C., the residence time of the suspension in the heating coil measured at the measuring point (9). The temperature is adjusted to 10 to 300 seconds (preferably 60 seconds). During this residence time, β-carotene dissolves in the solubilizer with simultaneous isomerization. The solution exiting the heating coil is turbulently mixed in the mixing chamber (6) with the aqueous phase which is likewise sent from the vessel (4) into the mixing chamber by the pump (5). A micellar β-carotene solution is produced in the mixing chamber. The aqueous phase is 10-80
° C, preferably 25 ° C. The aqueous phase may contain a preservative, for example benzyl alcohol, at a concentration of 0.5-5% of the final product. When the temperature of the solubilized substance downstream of the mixing chamber is measured at the measurement position (10), it is 40 to 80 ° C. The product is poured into a vessel (8) via a pressure regulator (7) adjusted to 10-50 bar. The content of active substance depends on the concentration and the flow rate chosen in each case and is usually from 0.5 to 6%, preferably 4%.
【0011】新規方法でも使用される慣例の酸化防止剤
の例は、次のものである:ブチル化ヒドロキシトルエン
又はヒドロキシアニソール及びd,l−α−トコフェロ
ール。酸化防止剤は、一般に、使用β−カロテンに対し
て10〜20重量%の量で使用される。Examples of conventional antioxidants also used in the novel process are: butylated hydroxytoluene or hydroxyanisole and d, l-α-tocopherol. Antioxidants are generally used in amounts of 10 to 20% by weight, based on the β-carotene used.
【0012】慣例で認められている例えば次の防腐剤を
使用するのも有利である:β−フェニルエチルアルコー
ル、β−フェノキシエチルアルコール及びベンジルアル
コール、特にベンジルアルコール。It is also advantageous to use the customary accepted preservatives, for example: β-phenylethyl alcohol, β-phenoxyethyl alcohol and benzyl alcohol, especially benzyl alcohol.
【0013】新規方法は、非常に安定な注射用溶液を提
供するβ−カロテン可溶化物を製造するために使用する
ことができる。注射可能なβ−カロテン可溶化物の生物
学的認容性は、経口投与されたβ−カロテンのそれより
も高い。この高い生物学的認容性は、血液中の最大β−
カロテン濃度により示され、これは、例えばウマ、ウシ
及びブタで、経口投与後よりも10〜100倍高い。β
−カロテン可溶化物の注射は、農業用家畜、例えばウ
マ、ウシ、ブタ及びウサギの繁殖力を、妊娠動物の率及
び正常出産の数を増加することにより改良するために使
用される。The novel method can be used to produce a β-carotene solubilizate which provides a very stable solution for injection. The biological tolerability of injectable β-carotene lysates is higher than that of orally administered β-carotene. This high biological tolerability means that the maximum β-
Indicated by carotene concentration, which is for example in horses, cattle and pigs 10 to 100 times higher than after oral administration. β
-Injection of carotene lysate is used to improve the fertility of agricultural livestock such as horses, cattle, pigs and rabbits by increasing the rate of pregnant animals and the number of normal births.
【0014】新規方法における熱異性化の調節は、結果
として貯蔵安定性及び生理学的活性に好適である異性体
比を生じる溶解温度及び滞留時間を選択することにより
達成される。The control of thermal isomerization in the novel process is achieved by selecting a dissolution temperature and a residence time which results in isomer ratios which are favorable for storage stability and physiological activity.
【0015】[0015]
【実施例】13−ヒドロキシステアリン酸250g及び
ブチル化ヒドロキシトルエン10g中のβ−カロテンX
g(表参照)の懸濁液を70℃に前加熱した容器に入れ
た。この懸濁液を高圧ポンプ(2)により、2 l/h
の速度で、油浴中に浸した加熱コイル中に供給した。約
160℃の熱伝達油を有する内径2mm及び長さ3m、
6m又は12mに対して、滞留時間をそれぞれ17、3
4又は68秒に設定した。これらの時間は、全ての場合
に、β−カロテンを乳化剤中に溶かすのに十分であっ
た。加熱コイル中での前記の滞留時間の後に、β−カロ
テン溶液をT型混合室に入れ、そこでこれを、180℃
で高圧ポンプ(5)を用いて5 l/hで供給した脱イ
オン水690gと乱流混合させた。25バールの圧力下
で、生成物を圧力調節バルブを介して排出させた。あら
ゆる場合に、結果として暗赤色のミセル状β−カロテン
溶液が生じた。生成物は、60℃であった。活性物質含
有率は、方法に依り4.3〜5.5%であった。準弾性
光散乱により測定された可溶化物中のミセル直径は、2
0〜30nmであった。EXAMPLES β-Carotene X in 250 g of 13-hydroxystearic acid and 10 g of butylated hydroxytoluene
g (see table) was placed in a container preheated to 70 ° C. This suspension was pumped to 2 l / h by a high pressure pump (2).
At a rate of 1 mm into a heating coil immersed in an oil bath. 2 mm inner diameter and 3 m length with heat transfer oil at about 160 ° C.
For 6m or 12m, the residence time is 17, 3 respectively.
It was set to 4 or 68 seconds. These times were in all cases sufficient to dissolve β-carotene in the emulsifier. After said residence time in the heating coil, the β-carotene solution is introduced into a T-type mixing chamber where it is brought to 180 ° C.
And turbulent mixing with 690 g of deionized water supplied at 5 l / h using a high pressure pump (5). At a pressure of 25 bar, the product was discharged via a pressure regulating valve. In all cases, a dark red micellar β-carotene solution resulted. The product was at 60 ° C. The active substance content was 4.3-5.5% depending on the method. The micelle diameter in the solubilizate measured by quasi-elastic light scattering is 2
It was 0 to 30 nm.
【0016】次の表は、測定された異性体比を包含する
実験パラメータ及び測定データを示す。The following table shows the experimental parameters and measured data, including the measured isomer ratios.
【0017】 表 実験No. 1 2 3 4 5 6 ──────────────────────────────────── β−カロテン 重量 [g] 50 50 42.5 42.5 42.5 50 加熱コイル 長さ [m] 3 12 12 3 6 6 滞留時間[sec] 17 68 68 17 34 34 温度 溶液 [℃] 158 153-160 150 159 169 162 可溶化物 [℃] 58 57 60 60 61 64 可溶化物の特性 β−カロテン 含有率[重量%] 4.9 4.5 4.3 4.5 4.6 5.5 ミセル寸法[nm] 30±25% 21±30 20±22 20±22 21±20 22±28 pH 7.0 6.9 7.0 6.7 7.0 6.7 異性体含有率 全−トランス[%注)] 66.4 36.9 38.0 56.6 50.6 例5 13−シス[%注)] 18.1 21.7 20.7 23.2 17.5 と 9−シス[%注)] 4.1 22.5 21.9 5.3 16.4 同じ 注)450nmでのHPLCにおける面積%Table Experiment No. 1 2 3 4 5 6 ──────────────────────────────────── β-carotene Weight [g] 50 50 42.5 42.5 42.5 50 Heating coil length [m] 3 12 12 3 6 6 Residence time [sec] 17 68 68 17 34 34 Temperature Solution [° C] 158 153-160 150 159 169 162 Solubilized material [° C] 58 57 60 60 61 64 Characteristics of solubilized product β-carotene content [wt%] 4.9 4.5 4.3 4.5 4.6 5.5 micelle size [nm] 30 ± 25% 21 ± 30 20 ± 22 20 ± 22 21 ± 20 22 ± 28 pH 7.0 6.9 7.0 6.7 7.0 6.7 Isomers content All-trans [% Note)] 66.4 36.9 38.0 56.6 50.6 Example 5 13-cis [% Note]] 18.1 21.7 20.7 23.2 17.5 and 9-cis [% Note]] 4.1 22.5 21.9 5.3 16.4 Same Note) Area% in HPLC at 450nm
【図1】図1は、β−カロテン可溶化物製造装置であ
る。FIG. 1 is an apparatus for producing a solubilized β-carotene.
【符号の説明】 1 容器、 2 ポンプ、 3 加熱コイル、
4 容器、 5ポンプ、 6 混合室、 7 圧
力調節器、 8 容器、 9 温度計、 10
温度計[Explanation of symbols] 1 container, 2 pump, 3 heating coil,
4 container, 5 pump, 6 mixing chamber, 7 pressure regulator, 8 container, 9 thermometer, 10
thermometer
───────────────────────────────────────────────────── フロントページの続き (72)発明者 エーリク リュートデッケ ドイツ連邦共和国 ムッターシュタット トーマス−マン−シュトラーセ 27 (72)発明者 ヨアヒム ウー. シュナイダー ドイツ連邦共和国 ヴァイゼンハイム プラウザーシュトラーセ 17 (72)発明者 ペーター パウル ホッペ ドイツ連邦共和国 ヴァッヒェンハイム アム ハウエンシュタイン 13 (72)発明者 フリードリッヒ−ヴィルヘルム レンス マン ドイツ連邦共和国 バート デュルクハ イム フィリップ−ファウト−シュトラ ーセ 6 (58)調査した分野(Int.Cl.7,DB名) A61K 31/015 A61K 9/08 B01F 3/08 C07B 63/04 CA(STN)──────────────────────────────────────────────────続 き Continued on the front page (72) Inventor Erik Ludecke, Germany Mutterstadt Thomas-Mann-Strasse 27 (72) Inventor Joachim Wu. Schneider Germany Weisenheim-Prowserstrasse 17 (72) Inventor Peter Paul Hoppe Germany Wachenheim am Hauenstein 13 (72) Inventor Friedrich-Wilhelm Lensmann Germany Bad-Dürkha im Phillip-Faut-Stra Case 6 (58) Field surveyed (Int. Cl. 7 , DB name) A61K 31/015 A61K 9/08 B01F 3/08 C07B 63/04 CA (STN)
Claims (1)
熱して均質溶液を得、これを水の添加により100℃よ
り低く急速冷却し、引き続き所望の最終濃度のβ−カロ
テンに調節することによるβ−カロテン可溶化物の連続
的製法において、20〜80℃に前加熱された、乳化剤
中のβ−カロテン1〜40重量%の懸濁液を、熱伝達油
中に置かれた加熱コイルにポンプ導通し、ここで可溶化
混合物は、120〜180℃であり、かつ滞留時間は、
10〜300秒であり、かつ均質溶液を混合室中で、か
なりの量の水と、10〜80℃で乱流混合させて、β−
カロテン0.5〜6重量%を含有する可溶化物を生ぜし
め、かつ必要に応じて所望の最終濃度に希釈することを
特徴とする、β−カロテン可溶化物の連続的製法。1. Heating of β-carotene with an emulsifier for a short time to obtain a homogeneous solution, which is rapidly cooled to below 100 ° C. by addition of water and subsequently adjusted to the desired final concentration of β-carotene. In a continuous process for the preparation of β-carotene solubilizate, a suspension of 1-40% by weight of β-carotene in an emulsifier, preheated to 20-80 ° C., is placed in a heating coil Where the solubilized mixture is at 120-180 ° C. and the residence time is
10-300 seconds and the homogeneous solution is turbulently mixed with a considerable amount of water in a mixing chamber at 10-80 ° C.
A continuous process for producing a solubilized β-carotene, characterized in that a solubilized product containing 0.5 to 6% by weight of carotene is produced and, if necessary, diluted to a desired final concentration.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4031094.9 | 1990-10-02 | ||
DE4031094A DE4031094A1 (en) | 1990-10-02 | 1990-10-02 | METHOD FOR PRODUCING STABLE INJECTABLE (BETA) CAROTINE SOLUBILISATES |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH04247028A JPH04247028A (en) | 1992-09-03 |
JP3105307B2 true JP3105307B2 (en) | 2000-10-30 |
Family
ID=6415401
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP03248638A Expired - Fee Related JP3105307B2 (en) | 1990-10-02 | 1991-09-27 | Continuous production of solubilized β-carotene |
Country Status (7)
Country | Link |
---|---|
US (1) | US5453447A (en) |
EP (1) | EP0479066B1 (en) |
JP (1) | JP3105307B2 (en) |
CA (1) | CA2051978A1 (en) |
DE (2) | DE4031094A1 (en) |
DK (1) | DK0479066T3 (en) |
ES (1) | ES2066306T3 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5612485A (en) * | 1992-06-04 | 1997-03-18 | Betatene Ltd Of Cheltenham | High cis beta-carotene composition |
DK19393D0 (en) * | 1993-02-19 | 1993-02-19 | Danochemo As | PROCEDURE FOR PREPARING A WATER DISPERSIBLE POWDER-CAROTENOID PREPARATION |
DE19609538A1 (en) * | 1996-03-11 | 1997-09-18 | Basf Ag | Finely divided carotenoid and retinoid suspensions and process for their preparation |
AU696956B2 (en) * | 1993-03-22 | 1998-09-24 | Betatene Pty Ltd | Water dispersible therapeutic compounds |
PT689426E (en) * | 1993-03-22 | 2000-11-30 | Cognis Australia Pty Ltd | THERAPEUTIC AGENT FOR THE TREATMENT OF MELANOMAS |
US5843334A (en) * | 1994-06-20 | 1998-12-01 | Nippon Shinyaku Co., Ltd. | Method of producing emulsions and an emulsification apparatus |
EP0806946A2 (en) * | 1995-02-03 | 1997-11-19 | Basf Aktiengesellschaft | Use of carotinoids for preparing medicaments for treating dermatoses |
DE19609477A1 (en) * | 1996-03-11 | 1997-09-18 | Basf Ag | Stable aqueous solubilisates of carotenoids and vitamins |
DE19609476A1 (en) * | 1996-03-11 | 1997-09-18 | Basf Ag | Stable parenteral administration suitable carotenoid emulsions |
DE19653410A1 (en) * | 1996-12-20 | 1998-06-25 | Basf Ag | Use of carotenoid solubilisates for coloring food and pharmaceutical preparations |
DE19838636A1 (en) | 1998-08-26 | 2000-03-02 | Basf Ag | Carotenoid formulations containing a mixture of beta-carotene, lycopene and lutein |
DE69938875D1 (en) * | 1998-11-13 | 2008-07-17 | William A Heriot | |
US6855296B1 (en) | 1998-11-13 | 2005-02-15 | Optime Therapeutics, Inc. | Method and apparatus for liposome production |
AT408186B (en) * | 1998-12-15 | 2001-09-25 | Sanochemia Pharmazeutika Ag | AQUEOUS PREPARATION OF BETA CAROTINE |
EP1227082B1 (en) * | 2001-01-24 | 2004-06-16 | Kuraray Co., Ltd. | Process for producing carotenoid emulsion |
DE10221212A1 (en) * | 2002-05-13 | 2003-11-27 | Andreas Maack | Soluble composition containing sporopollenin and use |
US20060182863A1 (en) * | 2003-03-28 | 2006-08-17 | Kuraray Co., Ltd. | Process for producing carotenoid emulsions |
US20110137243A1 (en) * | 2007-09-06 | 2011-06-09 | Abbott Cardiovascular Systems Inc. | Coating On A Balloon Device |
JP5680275B2 (en) | 2009-01-20 | 2015-03-04 | 富士フイルム株式会社 | Emulsion composition, food and cosmetic containing the emulsion composition |
US9295663B2 (en) | 2010-07-14 | 2016-03-29 | Abbott Cardiovascular Systems Inc. | Drug coated balloon with in-situ formed drug containing microspheres |
US20140023712A1 (en) * | 2012-07-20 | 2014-01-23 | Basf Se | Aqueous Transparent Oil-In-Water Emulsion Comprising an Emulsified Carotenoid |
MX361455B (en) | 2012-12-19 | 2018-12-06 | Novus Int Inc | Xanthophyll compositions and methods of use. |
US11547675B2 (en) * | 2015-08-10 | 2023-01-10 | Purdue Research Foundation | Methods and systems for depositing active ingredients on substrates |
CN112841645A (en) * | 2021-01-14 | 2021-05-28 | 江南大学 | Preparation method of beta-carotene microcapsule |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2976024A (en) * | 1954-10-06 | 1961-03-21 | Pure Oil Co | Apparatus for preparing colloidal dispersions |
US3932634A (en) * | 1973-06-28 | 1976-01-13 | Pfizer Inc. | High potency vitamin water dispersible formulations |
DE2526938C2 (en) * | 1975-02-14 | 1982-04-22 | F. Hoffmann-La Roche & Co. AG, 4002 Basel | Vitamin preparations |
DE3048000A1 (en) * | 1980-12-19 | 1982-07-15 | Basf Ag | STABLE INJECTABLE (BETA) CAROTINE SOLUBILISATES AND METHOD FOR THE PRODUCTION THEREOF |
US4895452A (en) * | 1988-03-03 | 1990-01-23 | Micro-Pak, Inc. | Method and apparatus for producing lipid vesicles |
-
1990
- 1990-10-02 DE DE4031094A patent/DE4031094A1/en not_active Withdrawn
-
1991
- 1991-09-20 EP EP91116027A patent/EP0479066B1/en not_active Expired - Lifetime
- 1991-09-20 DE DE59103790T patent/DE59103790D1/en not_active Expired - Fee Related
- 1991-09-20 ES ES91116027T patent/ES2066306T3/en not_active Expired - Lifetime
- 1991-09-20 CA CA002051978A patent/CA2051978A1/en not_active Abandoned
- 1991-09-20 DK DK91116027.3T patent/DK0479066T3/en active
- 1991-09-27 JP JP03248638A patent/JP3105307B2/en not_active Expired - Fee Related
- 1991-10-01 US US07/769,025 patent/US5453447A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DK0479066T3 (en) | 1995-02-13 |
JPH04247028A (en) | 1992-09-03 |
EP0479066A2 (en) | 1992-04-08 |
EP0479066A3 (en) | 1993-03-10 |
CA2051978A1 (en) | 1992-04-03 |
US5453447A (en) | 1995-09-26 |
DE59103790D1 (en) | 1995-01-19 |
EP0479066B1 (en) | 1994-12-07 |
DE4031094A1 (en) | 1992-04-09 |
ES2066306T3 (en) | 1995-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3105307B2 (en) | Continuous production of solubilized β-carotene | |
JP2572877B2 (en) | Novel production method of colloid-dispersed carotenoid preparation | |
JPS5871844A (en) | Low fat spread | |
JP2002519187A (en) | Method for producing aqueous emulsion or suspension | |
Cespi et al. | Evaluation of thermosensitive poloxamer 407 gel systems for the sustained release of estradiol in a fish model | |
SK85194A3 (en) | Emulsions with content of grease and method of their manufacture | |
JPH02174927A (en) | O/w type multiphase emulsion and preparation thereof | |
CN113288865B (en) | Preparation method of progesterone vaginal gel | |
CN110302141A (en) | Diclofenac sodium injection situ-gel and preparation method thereof | |
JP4283892B2 (en) | Composition having biological activity | |
US20060228408A1 (en) | Drug delivery system | |
US6171637B1 (en) | Inversion process for making fat continuous spreads | |
CN111012735A (en) | Preparation method of emulsifiable paste under alkaline condition | |
US11331275B2 (en) | Bexarotene softgel capsule and preparation method thereof | |
CN105343002B (en) | A kind of Etoricoxib oral microemulsion preparation and preparation method thereof | |
JP2896185B2 (en) | Liquid preparation for bile acid and method for producing the same | |
CN105878182A (en) | Preparation method of clevidipine butyrate injection fat emulsion | |
NL2033322B1 (en) | Baicalin-calcium alginate thermosensitive nanogel as well as preparation method and application thereof | |
CN102657851B (en) | Recombinant human interferon alpha2b cream and preparation method thereof | |
CN104856951A (en) | Follicle stimulating hormone transdermal nanometer emulsion and preparation method thereof | |
WO2010045700A1 (en) | Method for preparing a veterinary suspension formulation for administering water-insoluble medicaments | |
US20020082306A1 (en) | Aqueous formulation of beta carotene | |
CN117064845A (en) | Reversible temperature-sensitive gel long-acting preparation for local injection of progesterone and preparation method thereof | |
CN113116891A (en) | Emulsifiable paste and preparation method thereof | |
TW200418516A (en) | Droplet dispersed ointment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20000725 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080901 Year of fee payment: 8 |
|
LAPS | Cancellation because of no payment of annual fees |